scholarly journals Emergencies and critical issues in Parkinson’s disease

2019 ◽  
pp. practneurol-2018-002075 ◽  
Author(s):  
Cristina Simonet ◽  
Eduardo Tolosa ◽  
Ana Camara ◽  
Francesc Valldeoriola
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Clinical Presentation ◽  
Early Recognition ◽  
Medical Intervention ◽  
Disease Course ◽  
Precipitating Factors ◽  
Critical Issues ◽  
Prompt Attention ◽  
Disease Specialist

Complications from Parkinson’s disease may develop over the disease course, sometimes unexpectedly, and require prompt or even urgent medical intervention. The most common are associated with aggravation of motor symptoms; serious non-motor complications, such as psychosis, orthostatic hypotension or sleep attacks, also occur. Here we review such complications, their clinical presentation, precipitating factors and management, including those related to using device-aided therapies. Early recognition and prompt attention to these critical situations is challenging, even for the Parkinson’s disease specialist, but is essential to prevent serious problems.

Neuropsychiatric manifestations of Parkinson’s disease

2016 ◽  
Vol 24 (6) ◽  
pp. 529-533 ◽  
Author(s):  
Rosa M Molina Ruiz ◽  
Andrew H Evans ◽  
Dennis Velakoulis ◽  
Jeffrey CL Looi
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Clinical Presentation ◽  
Early Recognition ◽  
Neuropsychiatric Symptoms ◽  
Systematic Search ◽  
Neuropsychiatric Manifestations

Objective: This clinical update review focuses on the classification and description of common neuropsychiatric manifestations in Parkinson’s disease (PD). Method: We conducted a systematic search of the literature using Pubmed and selected the most recent and relevant papers for this review. Results: Neuropsychiatric manifestations in PD are are very frequent and may arise from an abnormal psychopathological response to the disease, neurobiological changes related to the disease itself, complications of treatments or a combination of all of these. Conclusions: Neuropsychiatric symptoms may precede the motor clinical presentation of PD. Early recognition is essential.

Critical issues of the biopsychosocial treatment of Parkinson’s disease

2015 ◽  
Vol 156 (12) ◽  
pp. 472-478 ◽  
Author(s):  
Péter Kincses ◽  
Norbert Kovács ◽  
Kázmér Karádi ◽  
János Kállai
Keyword(s):  
Quality Of Life ◽  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Psychological Health ◽  
Interdisciplinary Approach ◽  
Cognitive Status ◽  
Psychological Burden ◽  
Her Family ◽  
Critical Issues

This paper is a summary report on the basic questions of the biopsychosocial approach to Parkinson’s disease. It deals with cognitive, affective and psychological health issues which significantly influence the outcome of the physical rehabilitation. In spite of the unchanged cognitive status, the psychological burden of the changes in the quality of life, the obstruction, the change in the affective tone, and the shrinking ability to fulfil social roles decrease the patient’s quality of life. An interdisciplinary approach is best suited for mitigating these effects. Not only the patient but also his/her family and environment is seriously affected by the disease and its consequences. Treatment and rehabilitation options for increasing or maintaining the quality of life of the affected patients are diverse, and significantly depend on the features of the health care system. The authors believe that the following review emphasizing health psychological principles may contribute to the work of professionals working in clinical and rehabilitational fields and through them may increase the quality of life of patients and their family. Orv. Hetil., 2015, 156(12), 472–478.

Neural Tissue Xenotransplantation: What is Needed Prior to Clinical Trials in Parkinson's Disease?

2000 ◽  
Vol 9 (2) ◽  
pp. 235-246 ◽  
Author(s):  
Roger A. Barker ◽  
A. Lisa Kendall ◽  
Håkan Widner ◽  
H. Widner ◽  
L. Larsson ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Clinical Trials ◽  
Human Tissue ◽  
Neural Tissue ◽  
Fetal Tissue ◽  
Suitable Material ◽  
Human Fetal Tissue ◽  
Critical Issues ◽  
Alternative Sources

Embryonic allografted human tissue in patients with Parkinson's disease has been shown to survive and ameliorate many of the symptoms of this disease. Despite this success, the practical problems of using this tissue coupled to the ethical restrictions of using aborted human fetal tissue have lead to an exploration for alternative sources of suitable material for grafting, including xenogeneic embryonic dopaminergic-rich neural tissue. Nevertheless, xenografted neural tissue itself generates a number of practical, ethical, safety, and immunological issues that have to be addressed prior to any clinical xenotransplant program. In this article we review these critical issues and set out the criteria that we consider need to be met in the development of our clinical xenotransplantation research programs. We advocate that these, or similar, criteria should be adopted and made explicit by other centers contemplating similar clinical trials.

scholarly journals Lipoprotein-Associated Phospholipase A2 Is a Risk Factor for Patients With Parkinson’s Disease

2021 ◽  
Vol 15 ◽  
Author(s):  
Zubo Wu ◽  
Suyuan Wu ◽  
Tao Liang ◽  
Lin Wang
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Logistic Regression ◽  
Risk Factor ◽  
Phospholipase A2 ◽  
Area Under The Curve ◽  
Diagnostic Value ◽  
Multivariable Logistic Regression Analysis ◽  
Disease Course ◽  
Clinical Value

ObjectiveTo explore the association between lipoprotein-related phospholipase A2 (Lp-PLA2) and the risk of Parkinson’s disease (PD).MethodsA case-control study involving 58 hospitalized PD patients and 60 healthy controls was carried out. Serum Lp-PLA2 level was detected. According to the disease course and severity, PD patients were subdivided to analyze the clinical value of Lp-PLA2. Relationship between Lp-PLA2 and PD risk was analyzed by logistic regression. Diagnostic value of Lp-PLA2 in PD patients was investigated using receiver’s operator characteristic curves.ResultsLp-PLA2 level was significantly higher in the PD patients compared with the controls, and was significantly and positively correlated with the Hoehn-Yahr (H&Y) stage. The serum Lp-PLA2 level and H&Y stage of PD patients with a longer disease course were significantly higher than those with a shorter disease course. PD patients with milder conditions had significantly lower serum Lp-PLA2 levels than patients with severe conditions. Multivariable logistic regression analysis indicated higher Lp-PLA2 level was an independent risk factor of PD patients. Moreover, the area under the curve for Lp-PLA2 was 0.703, which was between those of homocysteine and serum amylase A.ConclusionTo our knowledge, this is the first study to show that increased level of Lp-PLA2 is associated with the risk of PD. Lp-PLA2 may be used for early detection of PD, and provides an effective intervention target for clinical treatment of PD.

scholarly journals Clinical Presentation of Parkinson’s Disease: Experience of using Movement Disorder Society Clinical Diagnostic Criteria for Parkinson’s Disease

2021 ◽  
pp. 183-188
Author(s):  
Muhammad Rezeul Huq ◽  
M. A. Hannan ◽  
Md. Ahsan Habib ◽  
Ahad Mahmud Khan
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Movement Disorder ◽  
Diagnostic Criteria ◽  
Clinical Presentation ◽  
Neurodegenerative Disorder ◽  
Motor Symptom ◽  
Clinical Diagnostic ◽  
Movement Disorder Society ◽  
Clinical Diagnostic Criteria

Aims: Parkinson’s disease (PD) is a common neurodegenerative disorder. As no definite diagnostic tests are available, diagnosis is done mostly clinically. UK Brain Bank criteria is commonly used globally for that purpose. In this study we used Movement Disorder Society (MDS) Clinical Diagnostic Criteria to diagnose PD and document the clinical presentations. Study design: Descriptive cross-sectional study. Methodology: This study was carried out in the department of neurology, Bangabandhu Sheikh Mujib Medical University (BSMMU), Dhaka, from May 2018 to April 2019. Total 42 patients (4 clinically established and 38 clinically probable PD) were enrolled as study population according to Movement Disorder Society (MDS) Clinical Diagnostic Criteria - 2015 for PD. Their patterns of clinical presentation were recorded. Results: Among the PD patients, 31 were male and 11 were female. Mean age of all patients was 59.43 ± 11.34 years. The most common presenting feature was tremulous movement (90.5%) followed by slowness of movement (40.5%). Only 9% patients had early onset PD. All patients had history of positive response to dopaminergic therapy with documented resting tremor in 95.2%, and end-of-dose wearing off in 75.6%. Constipation was the commonest (69%) non motor symptom followed by sleep dysfunction (64.3%) & depression (50%). On examination- 100% patients had bradykinesia, 97.6% rest tremor, 95.2% rigidity, 21.4% mild dementia and 4.8% moderate dementia. Also 26.2% patients were found to have postural hypotension. 4 patients had red flag features- urinary retention was found in three patients and one patient suffered from recurrent early fall. Conclusion: MDS Clinical Diagnostic Criteria   help in accurate diagnosis of PD and include more clinical features which will help in formulating management plan.

scholarly journals Clinical presentation of Parkinson's disease among Sudanese patients

2009 ◽  
Vol 4 (3) ◽  
Author(s):  
K Khalid ◽  
A Hussien ◽  
K Khalafela ◽  
A Yonis ◽  
AA Eltoum ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Clinical Presentation
Sign in / Sign up

Export Citation Format

Share Document